Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348189 | 1.00 | NPSR1 (0.58) | NPSR1NAMPTCNR2SSTR3NPC1 | |
| SCHEMBL13495007 | 1.00 | NPSR1 (0.58) | NPSR1NAMPTCNR2SSTR3NPC1 | |
| SCHEMBL8740547 | 1.00 | NPSR1 (0.58) | NPSR1NAMPTCNR2SSTR3NPC1 | |
| SCHEMBL7348191 | 1.00 | NPSR1 (0.58) | NPSR1NAMPTCNR2SSTR3NPC1 | |
| SCHEMBL8740548 | 1.00 | NPSR1 (0.58) | NPSR1NAMPTCNR2SSTR3NPC1 | |
| SCHEMBL775118 | 0.89 | SSTR3 (0.61) | SSTR3NPC1RAB9AMMP2MMP7 | |
| SCHEMBL774564 | 0.85 | MMP2 (0.59) | SSTR3NPC1RAB9AMMP2MMP7 | |
| SCHEMBL29933914 | 0.83 | NPC1 (0.64) | NAMPTSSTR3NPC1RAB9AHDAC4 | |
| SCHEMBL14117665 | 0.83 | HDAC4 (0.52) | NPSR1NAMPTCNR2SSTR3NPC1 | |
| SCHEMBL29933088 | 0.83 | RAB9A (0.64) | NPSR1NAMPTCNR2SSTR3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| EP-4516777-A2 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-0719247-A4 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR INC (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5616808-A | Optically pure 1-amino-2-indanols | SEPRACOR, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5599985-A | Optically pure 1-amido-2-indanols | SEPRACOR, INC. (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0719247-A1 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5516943-A | Process for preparing cyclic CIS-1-amino-2-alkanols | SEPRACOR, INC. (US) | 1996-05-14 | — | — | US | disclosed |
| WO-1995007880-A1 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0594597-A1 | NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS | G.D. Searle & Co. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0594597-A4 | NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS. | SEARLE & CO (US) | 1993-04-30 | — | — | EP | disclosed |
| WO-1991012247-A1 | NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS | G.D. SEARLE & CO. (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | NPSR1 2467/4885NAMPT 3602/4885CNR2 324/4885 |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | PDGFRB, PDGFRA, PDGFA | NPSR1 1352/4885NAMPT 3916/4885CNR2 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.